ARCA biopharma, Inc.
ABIO
NASDAQ
Weiss Ratings | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Unrated | |||
Risk Index | Unrated | |||
Risk Grade | U | |||
Reward Grade | U | |||
Rating Factors | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | Unrated | |||
Growth Index | Unrated | |||
Efficiency Index | Unrated | |||
Solvency Index | Unrated | |||
Total Return Index | Unrated | |||
Volatility Index | Unrated | |||
Beta / Standard Deviation | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.18 | |||
Price History | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -- | |||
30-Day Total Return | -- | |||
60-Day Total Return | -- | |||
90-Day Total Return | -- | |||
Year to Date Total Return | -- | |||
1-Year Total Return | -- | |||
2-Year Total Return | -- | |||
3-Year Total Return | -- | |||
5-Year Total Return | -- | |||
52-Week High % Change | -- | |||
52-Week Low % Change | -- | |||
Price | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $4.49 | |||
52-Week Low Price | $1.56 | |||
52-Week Low Price (Date) | Jan 19, 2024 | |||
52-Week High Price (Date) | May 17, 2024 | |||
Valuation | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | -- | |||
Enterprise Value | -- | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.50 | |||
Earnings Per Share Growth | -- | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | 1.11 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | -- | |||
Enterprise Value/EBITDA (TTM) | -- | |||
Enterprise Value/EBIT | -- | |||
Market Cap Category | -- | |||
Dividends and Shares | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 14.51M | |||
Dividend Yield | 64.52% | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 720 940 2200 | |||
Address | 10170 Church Ranch Way Westminster, CO 80021 | |||
Website | www.arcabio.com | |||
Country | United States | |||
Year Founded | -- | |||
Profitability | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -14.62% | |||
Return on Equity | -- | |||
Income Statement | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -8.75M | |||
EBIT (TTM) | -8.76M | |||
Net Income (TTM) | -7.20M | |||
Net Income Avl. to Common (TTM) | -7.20M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | -80.95% | |||
EPS Diluted (TTM) | -0.50 | |||
EPS Diluted Growth (Q YOY) | -79.75% | |||
Balance Sheet | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 33.28M | |||
Cash Per Share (Q) | $2.29 | |||
Total Current Assets (Q) | 33.82M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 32.57M | |||
Current Ratio (Q) | 26.609 | |||
Book Value Per Share (Q) | $2.25 | |||
Total Assets (Q) | 33.84M | |||
Total Current Liabilities (Q) | 1.27M | |||
Total Debt (Q) | 24.00K | |||
Total Liabilities (Q) | 1.27M | |||
Total Common Equity (Q) | 32.57M | |||
Cash Flow | ABIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -- | |||
Cash from Financing (TTM) | 14.00K | |||
Net Change in Cash (TTM) | -6.87M | |||
Levered Free Cash Flow (TTM) | -5.08M | |||
Cash from Operations (TTM) | -6.89M | |||